← Leaderboards
Bruce R. Montgomery
Va Puget Sound Healthcare System
$652,985
Attributed
$652,985
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $230.8K · FY2005–25$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$652,985 · 3
VA$0 · 2
By mechanism
R01$603,043 · 1
M01$49,942 · 2
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Va Puget Sound Healthcare System
Same institution · by research overlap
- Jose M. Garcia$4,005,580
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorToxic EffectResponsePathway InteractionsPersonalized CarePharmaceutical PreparationsDecision MakingMutationMetastatic Prostate CancerDna RepairAdvanced Prostate CancerDesignDna DamageFutureHomologous RecombinationEffectiveness TestingGenesDna Repair PathwayDna Repair DisorderCancer EtiologyCessation Of LifeBiological MarkersMalignant Neoplasm Of Prostate
Grant awards (17)
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency$0
I01 · FY2025 · VA · contact PI
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)$0
I01 · FY2025 · VA · contact PI
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)$0
I01 · FY2024 · VA · contact PI
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency$0
I01 · FY2024 · VA · contact PI
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency$0
I01 · FY2023 · VA · contact PI
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)$0
I01 · FY2023 · VA · contact PI
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)$0
I01 · FY2022 · VA · contact PI
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)$0
I01 · FY2021 · VA · contact PI
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency$0
I01 · FY2021 · VA · contact PI
Multicenter phase II study of first-line carboplatin followed by docetaxel versus first-line docetaxel followed by carboplatin for treatment of castration resistant prostate cancer$0
I01 · FY2020 · VA · contact PI
EGFR VACCINE TRIAL$1,066
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF AN EGFRVIII PEPTIDE-BASED VACCINE IN PATIENTS WITH CANCER$10,750
M01 · FY2006 · RR · contact PI
PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII$206,562
R01 · FY2005 · CA
A PHASE I STUDY OF AN EGFRVIII PEPTIDE BASE VACCINE IN PATIENTS WITH CANCER$24,246
M01 · FY2005 · RR
PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII$200,960
R01 · FY2004 · CA
A phase I study of an EGFRvIII peptide base vaccine in patients with cancer$13,880
M01 · FY2004 · RR
PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII$195,521
R01 · FY2003 · CA